Lucid Diagnostics releases data from first clinical utility study of EsoGuard

Lucid Diagnostics (LUCD), a majority-owned subsidiary of PAVmed (PAVM), announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard, CLUE, study. This is the Company’s first report of prospective data from multiple physicians demonstrating real-world clinical utility of EsoGuard Esophageal DNA testing for the detection of esophageal precancer; and supplements its recently released positive data from a retrospective analysis of EsoGuard’s clinical utility in firefighters. “Prospective clinical utility data involving multiple physicians provides the strongest level of evidence to payors, and other stakeholders, that a diagnostic test such as EsoGuard has real-world clinical utility driving appropriate medical decision making,” said Victoria T. Lee, M.D., PAVmed’s Senior Vice President and Chief Medical Officer of PAVmed, who oversees all of Lucid’s clinical research activities. “We designed CLUE to demonstrate to payors that a diverse group of physicians across multiple centers will clinically utilize EsoGuard to appropriately refer at-risk patients with positive results for confirmatory endoscopy, and not refer those with negative results unless another indication for endoscopy emerges. These outstanding interim results in our first 275 patients document that the physicians do make the appropriate referrals, consistent with professional society guidelines. We continue to expand the number of study sites and enroll additional patients in the CLUE study. We plan to release subsequent reports on a larger CLUE cohort along with additional clinical utility data documenting patient compliance with the endoscopy referral following a positive EsoGuard result.”